| London | |
| 0 | |
| Immunovadis was created in 2015 with the sole objective of discovering functional anti-HLA-G monoclonal anti-bodies for therapeutic use in cancer treatment. | |
| HLA-G Immunotherapy consists of stimulating the patient's own immune system against the patient's cancer. It involves injecting patients with Anti-Bodies that disable checkpoints and thereby increasing the activity of the immune system until the cancer cells are eliminated. HLA-G is perhaps the most unique and potentially the most important molecule in curing cancer. Immunovadis is presently raising capital for this purpose. | |
| Private Equity |
Fiche créée le 10/04/2016 par 
Guillaume vue 120 fois.